Pacific Biosciences
PACB
256 hedge funds and large institutions have $4.2B invested in Pacific Biosciences in 2021 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 87 increasing their positions, 79 reducing their positions, and 40 closing their positions.
28% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 40
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
10% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 79
4% more funds holding
Funds holding: 246 → 256 (+10)
3% more call options, than puts
Call options by funds: $21M | Put options by funds: $20.4M
1.87% less ownership
Funds ownership: 94.96% → 93.09% (-1.9%)
13% less capital invested
Capital invested by funds: $4.83B → $4.2B (-$629M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$88.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$74.9M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$61.9M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$61.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$23.3M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$21.2M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$14.9M |
| 4 |
SIG
Senator Investment Group
New York
|
-$14.1M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$13M |
PACB Hedge Fund Activity: Q4 2021 in Review
256 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2021, worth a combined $4.2B — down 13% from $4.83B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new PACB positions and 40 closed out — a net gain of 11 holders — while 87 added to existing stakes and 79 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $88.3M. The largest seller was HHLR Advisors, exiting entirely with an estimated $23.3M sold.
- 256 institutional investors held Pacific Biosciences (PACB) as of Q4 2021, up from 246 in Q3 2021.
- Funds reported $4.2B of Pacific Biosciences stock for Q4 2021, down 13% quarter-over-quarter.
- 51 funds opened new Pacific Biosciences positions in Q4 2021 and 40 closed out, a net change of +11 holders.
- The largest Pacific Biosciences buyer in Q4 2021 was ARK Investment Management, an estimated $88.3M added.
- The largest Pacific Biosciences seller in Q4 2021 was HHLR Advisors, an estimated $23.3M sold.
Based on aggregated 13F filings for Q4 2021.